Parkinson's disease and other α-synucleinopathies

被引:90
作者
Goedert, M [1 ]
机构
[1] MRC, Mol Biol Lab, Cambridge CB2 2QH, England
关键词
alpha-synuclein; Lewy body diseases; multiple system atrophy; Parkinson's disease; neurological disease;
D O I
10.1515/CCLM.2001.047
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 ;
摘要
Parkinson's disease is the most common movement disorder and the second most common neurodegenerative disease. Neuropathologically, it is characterized by the degeneration of nerve cells that develop filamentous inclusions in the form of Lewy bodies and Lewy neurites. Recent work has shown that rare, familial forms of Parkinson's disease are caused by missense mutations in the alpha -synuclein gene and that the filamentous lesions of Parkinson's disease are made of alpha -synuclein. The same is true of the Lewy body pathology that is associated with other neurodegenerative diseases, such as dementia with Lewy bodies. The filamentous inclusions of multiple system atrophy have also been found to be made of alpha -synuclein, thus providing an unexpected molecular link with Lewy body diseases. Recombinant alpha -synuclein assembles into filaments with similar morphologies to those found in the human diseases and with a cross-beta diffraction pattern characteristic of amyloid. The related proteins beta -synuclein and gamma -synuclein are poor at assembling into filaments. They are not present in the pathological filamentous lesions and have not been found to be linked to genetic disease. The new work has established the alpha -synucleinopathies as a major class of neurodegenerative disease.
引用
收藏
页码:308 / 312
页数:5
相关论文
共 59 条
[1]   Mice lacking α-synuclein display functional deficits in the nigrostriatal dopamine system [J].
Abeliovich, A ;
Schmitz, Y ;
Fariñas, I ;
Choi-Lundberg, D ;
Ho, WH ;
Castillo, PE ;
Shinsky, N ;
Verdugo, JMG ;
Armanini, M ;
Ryan, A ;
Hynes, M ;
Phillips, H ;
Sulzer, D ;
Rosenthal, A .
NEURON, 2000, 25 (01) :239-252
[2]   Lewy body in neurodegeneration with brain iron accumulation type 1 is immunoreactive for α-synuclein [J].
Arawaka, S ;
Saito, Y ;
Murayama, S ;
Mori, H .
NEUROLOGY, 1998, 51 (03) :887-889
[3]   Parkinson's disease-associated α-sylnuclein is more fibrillogenic than β- and γ-synuclein and cannot cross-seed its homologs [J].
Biere, AL ;
Wood, SJ ;
Wypych, J ;
Steavenson, S ;
Jiang, YJ ;
Anafi, D ;
Jacobsen, FW ;
Jarosinski, MA ;
Wu, GM ;
Louis, JC ;
Martin, F ;
Narhi, LO ;
Citron, M .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2000, 275 (44) :34574-34579
[4]   Persyn, a member of the synuclein family, influences neurofilament network integrity [J].
Buchman, VL ;
Adu, J ;
Pinon, LGP ;
Ninkina, NN ;
Davies, AM .
NATURE NEUROSCIENCE, 1998, 1 (02) :101-103
[5]  
Buchman VL, 1998, J NEUROSCI, V18, P9335
[6]  
Clayton DF, 1999, J NEUROSCI RES, V58, P120, DOI 10.1002/(SICI)1097-4547(19991001)58:1<120::AID-JNR12>3.0.CO
[7]  
2-E
[8]   Fibrils formed in vitro from α-synuclein and two mutant forms linked to Parkinson's disease are typical amyloid [J].
Conway, KA ;
Harper, JD ;
Lansbury, PT .
BIOCHEMISTRY, 2000, 39 (10) :2552-2563
[9]   Acceleration of oligomerization, not fibrillization, is a shared property of both α-synuclein mutations linked to early-onset Parkinson's disease:: Implications for pathogenesis and therapy [J].
Conway, KA ;
Lee, SJ ;
Rochet, JC ;
Ding, TT ;
Williamson, RE ;
Lansbury, PT .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2000, 97 (02) :571-576
[10]   Accelerated in vitro fibril formation by a mutant α-synuclein linked to early-onset Parkinson disease [J].
Conway, KA ;
Harper, JD ;
Lansbury, PT .
NATURE MEDICINE, 1998, 4 (11) :1318-1320